DE2532276C3 - Verfahren zur Reinigung von Human-Antilymphozytenserum - Google Patents
Verfahren zur Reinigung von Human-AntilymphozytenserumInfo
- Publication number
- DE2532276C3 DE2532276C3 DE19752532276 DE2532276A DE2532276C3 DE 2532276 C3 DE2532276 C3 DE 2532276C3 DE 19752532276 DE19752532276 DE 19752532276 DE 2532276 A DE2532276 A DE 2532276A DE 2532276 C3 DE2532276 C3 DE 2532276C3
- Authority
- DE
- Germany
- Prior art keywords
- serum
- human
- antilymphocyte
- tissue
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000003293 antilymphocyte serum Anatomy 0.000 title claims description 18
- 238000000034 method Methods 0.000 title claims description 14
- 238000000746 purification Methods 0.000 title description 3
- 210000002966 serum Anatomy 0.000 claims description 33
- 239000007788 liquid Substances 0.000 claims description 25
- 210000005059 placental tissue Anatomy 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 12
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000009102 absorption Effects 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000001556 precipitation Methods 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 230000000781 anti-lymphocytic effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 229960004279 formaldehyde Drugs 0.000 description 6
- 235000019256 formaldehyde Nutrition 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000003825 pressing Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241000283073 Equus caballus Species 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 108010074605 gamma-Globulins Proteins 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- -1 2-ethoxy Chemical group 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000010932 ethanolysis reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 231100000355 lymphocytotoxic Toxicity 0.000 description 1
- 230000001391 lymphocytotoxic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Treatment And Processing Of Natural Fur Or Leather (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7425176A FR2278343A1 (fr) | 1974-07-19 | 1974-07-19 | Procede de preparation d'un serum antilymphocytaire humain et nouveau serum antilymphocytaire humain obtenu selon ce procede |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2532276A1 DE2532276A1 (de) | 1976-01-29 |
| DE2532276B2 DE2532276B2 (de) | 1979-08-23 |
| DE2532276C3 true DE2532276C3 (de) | 1980-05-22 |
Family
ID=9141492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752532276 Expired DE2532276C3 (de) | 1974-07-19 | 1975-07-18 | Verfahren zur Reinigung von Human-Antilymphozytenserum |
Country Status (7)
| Country | Link |
|---|---|
| BE (1) | BE831543A (en:Method) |
| DE (1) | DE2532276C3 (en:Method) |
| ES (1) | ES439513A1 (en:Method) |
| FR (1) | FR2278343A1 (en:Method) |
| GB (1) | GB1494853A (en:Method) |
| NL (1) | NL176053C (en:Method) |
| SE (1) | SE433172B (en:Method) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115232783B (zh) * | 2022-08-03 | 2023-03-10 | 武汉中生毓晋生物医药有限责任公司 | 抗人t细胞猪免疫球蛋白的制备方法及醛化胎盘 |
-
1974
- 1974-07-19 FR FR7425176A patent/FR2278343A1/fr active Granted
-
1975
- 1975-07-17 ES ES439513A patent/ES439513A1/es not_active Expired
- 1975-07-18 NL NL7508639A patent/NL176053C/xx not_active IP Right Cessation
- 1975-07-18 BE BE158450A patent/BE831543A/xx not_active IP Right Cessation
- 1975-07-18 DE DE19752532276 patent/DE2532276C3/de not_active Expired
- 1975-07-18 GB GB3032075A patent/GB1494853A/en not_active Expired
- 1975-07-18 SE SE7508238A patent/SE433172B/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE2532276B2 (de) | 1979-08-23 |
| BE831543A (fr) | 1975-11-17 |
| FR2278343B1 (en:Method) | 1978-08-11 |
| NL176053C (nl) | 1985-02-18 |
| NL176053B (nl) | 1984-09-17 |
| DE2532276A1 (de) | 1976-01-29 |
| ES439513A1 (es) | 1977-02-16 |
| SE433172B (sv) | 1984-05-14 |
| GB1494853A (en) | 1977-12-14 |
| NL7508639A (nl) | 1976-01-21 |
| FR2278343A1 (fr) | 1976-02-13 |
| SE7508238L (sv) | 1976-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2606118C2 (de) | Verfahren zur Herstellung eines gereinigten Gamaglobulins und intravenös verabreichbares Arzneimittel | |
| DE3825429C2 (de) | Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt | |
| DE2936047C2 (en:Method) | ||
| EP0122909B1 (de) | Immunglobulin-G-hältige Fraktion | |
| EP0659767B2 (de) | Verfahren zur Herstellung eines Konzentrates von Anti-D-Immunoglobulin G und pharmazeutische Zusammensetzung, die dieses enthält | |
| DE3927111C3 (de) | Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate | |
| DE2801123A1 (de) | Verfahren zur herstellung eines intravenoes applizierbaren serumeiweiss- praeparates | |
| DE2458327A1 (de) | Rinder-immunoglobulin-isolierungsverfahren | |
| DE2827027B2 (de) | Gefriergetrocknetes natives T -globulin-Präparat zur intravenösen Verabreichung | |
| EP0085747B2 (de) | Intravenös verabreichbares humanes Immunglobulin und Verfahren zu dessen Herstellung | |
| DE69631229T2 (de) | Herstellung von virusinaktivierten intravenös injektierbaren Globulin aus Immunserum | |
| DE2301501B2 (de) | Verfahren zur gewinnung eines stabilen, von hypotensiven stoffen freien plasmaproteins | |
| DE2734150A1 (de) | Verfahren zur gewinnung von human- lysozym | |
| DE2532276C3 (de) | Verfahren zur Reinigung von Human-Antilymphozytenserum | |
| DE1076888B (de) | Verfahren zur Gewinnung atmungsfoerdernder Wirkstoffe fuer therapeutische Zwecke | |
| DE2404265C3 (de) | Verfahren zum Abreichen von Immunglobulinen | |
| DE3344656A1 (de) | Verfahren zur herstellung einer serumproteinloesung | |
| DE1617332B2 (de) | Verfahren zum Isolieren eines wasserlöslichen Protein-Metall-Chelats mit antiphlogistischer Wirkung | |
| DE2515666B2 (de) | Piasminreiche Gammaglobulinfraktion, Verfahren zu deren Herstellung und das Verfahrensprodukt enthaltendes Gammaglobulinpräparat | |
| DE2440926C3 (de) | Injizierbarer inaktivierter Impfstoff gegen Hepatitis B und Verfahren zu seiner Herstellung | |
| DE2533183C3 (de) | Verfahren zum Herstellen gereinigter Immunglobuline | |
| EP0249167A2 (de) | Verfahren zur Herstellung einer pasteurisierten Immunglobulinpraeparation | |
| DE19611235C1 (de) | Mittel zur Steigerung der Ausbeute von Antikörpern in der Immunologie 2 | |
| AT226372B (de) | Dessaggregiertes Gammaglobulin und Verfahren zu seiner Herstellung | |
| AT387717B (de) | Verfahren zum bestimmen von unvertraeglichkeitsreaktionen verursachenden substanzen in therapeutisch und prophylaktisch anzuwendenden blutprodukten sowie verwendung des verfahrens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: BERENDT, T., DIPL.-CHEM. DR., PAT.-ANW., 8000 MUENCHEN |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: INSTITUT MERIEUX, LYON, RHONE, FR |
|
| 8328 | Change in the person/name/address of the agent |
Free format text: BERENDT, T., DIPL.-CHEM. DR. LEYH, H., DIPL.-ING. DR.-ING. HERING, H., DIPL.-ING., PAT.-ANWAELTE, 8000 MUENCHEN |